Eli Lilly and Company Aktie News

Eli Lilly and Nimbus Therapeutics have entered into a multiyear collaboration and exclusive licensing agreement to develop an oral treatment for obesity and other metabolic diseases.

Google stock is nearing a buy point in a flat base.

Nimbus Therapeutics said on Tuesday it has entered into a multi-year research and licensing agreement with Eli Lilly to develop artificial intelligence-driven new oral treatments for obesity and other metabolic diseases.

Eli Lilly (LLY) remains a Strong Buy, driven by robust GLP-1 demand and stellar execution, delivering a 34% total return since initial bullish coverage. LLY's Q3 results showed a 10% revenue and 19% EPS beat, with operating margin expanding from 40% to 48% YoY, and cash from operations surging to $8.8 billion. Flagship products Mounjaro and Zepbound posted 100%+ YoY revenue growth; late-stage p...

Eli Lilly briefly reached $1 trillion in market cap last year before retreating. The company has seen revenue soar in recent quarters thanks to its weight loss portfolio.

There are nine current $1 trillion club members and three companies that are within $120 billion of the milestone. Visa, Oracle, ExxonMobil, and Netflix could produce big gains over the next five years.

Eli Lilly stock is falling as rival Novo Nordisk hit a milestone in the area of weight-loss drugs. But Lilly has a rival drug in the pipeline.

Novo Nordisk's wildly successful obesity medicine is now available as a pill, making it the first GLP-1 pill for weight loss in the U.S.